Telix and Varian Launch Clinical Collaboration Combining Theranostics With EBRT

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) has entered a strategic clinical collaboration with Varian, a Siemens Healthineers company and a global leader in radiation oncology, to develop new clinical applications that pair Telix’s theranostic products with external beam radiation therapy (EBRT).

EBRT is a widely used, validated treatment for most solid malignant tumors and is typically delivered by radiation oncologists across multiple stages of cancer care. Telix and Varian plan to explore how integrating precision diagnostics and radiopharmaceutical theranostics into EBRT workflows could enhance patient selection, enable more targeted treatment approaches, and improve response monitoring.

The first investigational focus will be PSMA-PET imaging in prostate cancer radiotherapy patients. The companies aim to evaluate opportunities to use Telix’s Gozellix® and Illuccix® (both kits for the preparation of gallium-68 [68Ga] gozetotide injection) to support the selection of patients for EBRT, the development of personalized treatment plans—including within Varian’s Ethos adaptive radiotherapy—and the assessment of treatment response. The agreement includes both company-sponsored and investigator-led clinical studies.

While PSMA-PET is the initial priority, the collaboration is structured as a broader framework for additional co-development opportunities. Future work may include other Telix PET imaging candidates such as TLX250-CDx (Zircaix®) and TLX101-CDx (Pixclara®), along with potential therapeutic radiopharmaceuticals. The companies said combining theranostics with Varian’s EBRT technology positions radiation oncologists to help lead both definitive and palliative treatment strategies.

“Collaborating with Telix opens a powerful pathway to embed precision imaging and theranostics into the radiation therapy workflow, advancing how we personalize and optimize treatment decisions,” said Arthur Kaindl, MD, Head of Varian. “By combining Telix's strength in molecular imaging and radiopharmaceuticals with Varian's leadership in radiation therapy and treatment planning, we are shaping a future of more targeted, patient-focused cancer care.”

“This strategic partnership with Varian represents a transformative opportunity to bring precision imaging into the heart of radiation oncology,” said Christian Behrenbruch, PhD, Telix Group CEO and Managing Director. “Integrating theranostics into EBRT has the potential to improve patient outcomes… we are building alliances to explore new frontiers in personalized cancer care.”